| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | PFE | Common Stock | Options Exercise | $804,780 | +29,436 | +31% | $27.34 | 123,073 | 23 Feb 2024 | Direct | F1 |
| transaction | PFE | Common Stock | Tax liability | $59,184 | -2,132 | -1.7% | $27.76 | 120,941 | 23 Feb 2024 | Direct | F2 |
| transaction | PFE | Common Stock | Tax liability | $651,078 | -23,788 | -20% | $27.37 | 97,153 | 23 Feb 2024 | Direct | F3, F4 |
| holding | PFE | Common Stock | 6,301 | 23 Feb 2024 | By Rule 16b-3 Plan |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | PFE | Stock Appreciation Rights | Options Exercise | $0 | -29,436 | -100% | $0.000000* | 0 | 23 Feb 2024 | Common Stock | 29,436 | $27.34 | Direct |
| Id | Content |
|---|---|
| F1 | The reported transaction constitutes the earn-out of stock appreciation rights (including dividend equivalents thereon). |
| F2 | The reported transaction constitutes the withholding of shares to satisfy tax obligations in connection with earn-out of stock appreciation rights. |
| F3 | The reported transaction constitutes the withholding of shares to cover payment of exercise price in connection with earn-out of stock appreciation rights (including dividend equivalents thereon). |
| F4 | Under the terms of the settlement of the stock appreciation rights the 20-day average of the closing prices of Pfizer common stock ending on the settlement date is used. |